Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.

To investigate why human immunodeficiency virus type 2 (HIV-2) is less virulent than HIV-1, the evolution of coreceptor usage, autologous neutralization, envelope sequence and glycosylation was studied in sequentially obtained virus isolates and sera from four HIV-2-infected individuals. Neutralization of primary HIV-2 isolates was tested by a cell line-based assay and IgG purified from patients' sera. Significant autologous neutralization was observed for the majority (39 of 54) of the HIV-2 serum-virus combinations tested, indicating that neutralization escape is rare in HIV-2 infection. Furthermore, sera from 18 HIV-2 patients displayed extensive heterologous cross-neutralization when tested against a panel of six primary HIV-2 isolates. This indicates that HIV-2 is intrinsically more sensitive to antibody neutralization than HIV-1. In line with earlier reports, HIV-2 isolates could use several alternative receptors in addition to the major coreceptors CCR5 and CXCR4. Intrapatient evolution from CCR5 use to CXCR4 use was documented for the first time. Furthermore, CXCR4 use was linked to the immunological status of the patients. Thus, all CXCR4-using isolates, except one, were obtained from patients with CD4 counts below 200 cells microl(-1). Sequence analysis revealed an association between coreceptor usage and charge of the V3 loop of the HIV-2 envelope, as well as an association between the rate of disease progression and the glycosylation pattern of the envelope protein. Furthermore, HIV-2 isolates had fewer glycosylation sites in the V3 domain than HIV-1 (two to three versus four to five). It is proposed here that HIV-2 has a more open and accessible V3 domain than HIV-1, due to differences in glycan packing, and that this may explain its broader coreceptor usage and greater sensitivity to neutralizing antibodies.

[1]  H. Whittle,et al.  A Broad Range of Chemokine Receptors Are Used by Primary Isolates of Human Immunodeficiency Virus Type 2 as Coreceptors with CD4 , 1998, Journal of Virology.

[2]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Overbaugh,et al.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies , 1997, Journal of virology.

[4]  R. Thorstensson,et al.  Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2. , 1999, Virus research.

[5]  M. Dittmar,et al.  The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. , 2002, Virology.

[6]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[7]  L. Montagnier,et al.  Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160 , 1992, Journal of virology.

[8]  R. Weiss,et al.  HIV-2 antisera cross-neutralize HIV-1. , 1988, AIDS.

[9]  J. Albert,et al.  CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. , 2002, AIDS research and human retroviruses.

[10]  Philip R. Johnson,et al.  Correlation between env V1/V2 Region Diversification and Neutralizing Antibodies during Primary Infection by Simian Immunodeficiency Virus sm in Rhesus Macaques , 2004, Journal of Virology.

[11]  Sudhir Kumar,et al.  MEGA2: molecular evolutionary genetics analysis software , 2001, Bioinform..

[12]  H. Whittle,et al.  HIV-2-induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1. , 1991, AIDS.

[13]  F. Brun-Vézinet,et al.  Autologous neutralizing antibodies and viral load in HIV-2-infected individuals. , 1995, AIDS.

[14]  R. Doms,et al.  Human immunodeficiency virus type 2. , 2002, Journal of General Virology.

[15]  K. Ariyoshi,et al.  Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? , 1992, The Lancet.

[16]  A J Langlois,et al.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Bette T. Korber,et al.  Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.

[18]  I. Jones,et al.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein , 1996, Journal of virology.

[19]  J. Albert,et al.  Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates, Like HIV-1 Isolates, Frequently Use CCR5 but Show Promiscuity in Coreceptor Usage , 1999, Journal of Virology.

[20]  Jaap Goudsmit,et al.  N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* , 2001, The Journal of Biological Chemistry.

[21]  H. Whittle,et al.  No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients. , 2004, The Journal of infectious diseases.

[22]  O. Yoshie,et al.  Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. , 1999, Virology.

[23]  J. Nielsen,et al.  Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. , 1996, Virology.

[24]  D. Montefiori,et al.  Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. , 1999, AIDS research and human retroviruses.

[25]  S. Popper,et al.  Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. , 1999, The Journal of infectious diseases.

[26]  D. Ho,et al.  HIV-1 subtype and second-receptor use , 1996, Nature.

[27]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[28]  C. Debouck,et al.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Brun-Vézinet,et al.  Cellular and plasma viral load in patients infected with HIV‐2 , 1993, AIDS.

[30]  J. Albert,et al.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.

[31]  I. Thior,et al.  Slower heterosexual spread of HIV-2 than HIV-1 , 1994, The Lancet.

[32]  G. Simmons,et al.  Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo , 1999, Journal of Virology.

[33]  R. Doms,et al.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses , 1997, Journal of virology.

[34]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .

[35]  Michael Bunce,et al.  Evolution and transmission of stable CTL escape mutations in HIV infection , 2001, Nature.

[36]  B. Olde,et al.  HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use , 2003, AIDS.

[37]  A. Blaxhult,et al.  pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. , 2003, AIDS research and human retroviruses.

[38]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[39]  J. Levy,et al.  Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals , 1990, Journal of virology.

[40]  H. Whittle,et al.  Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. , 1998, Journal of human virology.

[41]  F. Dias,et al.  A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. , 1993, AIDS.

[42]  E. Fenyö,et al.  Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. , 1996, Immunology letters.

[43]  M. Cho,et al.  N-Linked Glycosylation Sites Adjacent to and within the V1/V2 and the V3 Loops of Dualtropic Human Immunodeficiency Virus Type 1 Isolate DH12 gp120 Affect Coreceptor Usage and Cellular Tropism , 2001, Journal of Virology.

[44]  M. Kimura A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences , 1980, Journal of Molecular Evolution.

[45]  J. Albert,et al.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.

[46]  J. Albert,et al.  Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. , 2000, Archives of internal medicine.

[47]  J. Albert,et al.  Biological phenotype of HIV type 2 isolates correlates with V3 genotype. , 1996, AIDS research and human retroviruses.

[48]  U. Bredberg,et al.  A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. , 1987, AIDS research and human retroviruses.

[49]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[50]  L. Arthur,et al.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[51]  I. Thior,et al.  Reduced rate of disease development after HIV-2 infection as compared to HIV-1. , 1994, Science.

[52]  J. Goudsmit,et al.  Neutralizing antibodies are positively associated with CD4+ T‐cell counts and T‐cell function in long‐term AIDS‐free infection , 1998, AIDS.

[53]  J. Albert,et al.  A new cell line-based neutralization assay for primary HIV type 1 isolates. , 2002, AIDS research and human retroviruses.

[54]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[55]  M. Uhlén,et al.  Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. , 1991, AIDS research and human retroviruses.

[56]  J. Albert,et al.  Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. , 1991, Virology.

[57]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[58]  R. Weiss,et al.  CD4-dependent and CD4-independent HIV-2: consequences for neutralization , 2003, AIDS.

[59]  L. Stamatatos,et al.  N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies , 2004, Journal of Virology.

[60]  H. Schuitemaker,et al.  CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia , 2005, Journal of Virology.

[61]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[62]  N. Saitou,et al.  The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.

[63]  P. Kaleebu,et al.  Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization , 1996, Journal of virology.

[64]  J. Albert,et al.  Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. , 1993, Virology.

[65]  R. Weiss,et al.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4 , 1992, Journal of virology.

[66]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[67]  W. Paxton,et al.  Intrapatient Alterations in the Human Immunodeficiency Virus Type 1 gp120 V1V2 and V3 Regions Differentially Modulate Coreceptor Usage, Virus Inhibition by CC/CXC Chemokines, Soluble CD4, and the b12 and 2G12 Monoclonal Antibodies , 2004, Journal of Virology.

[68]  J. Albert,et al.  REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.